梅州怀孕44天能做流产吗(梅州有关盆腔炎的治疗) (今日更新中)

CHENGDU, Sept. 3 (Xinhua) -- A list of this year's top 500 Chinese enterprises was unveiled in the city of Chengdu in southwest China's Sichuan Province on Saturday.The Sinopec Group was ranked first, with last year's revenues reaching 1.97 trillion yuan (307.81 billion U.S. dollars), followed by the China National Petroleum Corp. and State Grid Corp., whose revenues hit 1.72 trillion yuan and 1.53 trillion yuan last year, respectively.The rest of the top 10 was rounded out by the Industrial and Commercial Bank of China, China Mobile, China Railway Group, China Railway Construction Corp., China Construction Bank, China Life Insurance Co. and Agricultural Bank of China.The list is the 10th of its kind to be jointly released by the China Enterprise Confederation and the China Enterprise Directors Association. The threshold for entering the list was raised to 14.2 billion yuan in revenues, an increase over the 11.08-billion-yuan threshold used during the previous year.Revenues for China's top 500 companies rose 31.6 percent year-on-year to 36.31 trillion yuan in 2010, while their total assets increased by 18.4 percent to 108.1 trillion yuan, the two organizations said.The companies reported profits of 2.08 trillion yuan for last year, a rise of 38.67 percent from one year earlier.They paid 2.73 trillion yuan in taxes in 2010, accounting for 37.3 percent of the country's total tax revenues.

SAN FRANCISCO, Aug. 3 (Xinhua)-- Google's top legal officer on Wednesday posted a scathing blog post, accusing Microsoft, Apple, Oracle and other companies of waging "bogus" patent wars over smartphone technologies.More than 550,000 Android devices are activated daily, but the success of the mobile operating system has yielded "a hostile, organized campaign against Android by Microsoft, Oracle, Apple and other companies, waged through bogus patent," said Google Senior Vice President and Chief Legal Officer David Drummond."Microsoft and Apple have always been at each other's throats, so when they get into bed together you have to start wondering what's going on," wrote Drummond at the beginning of the blog post under the heading "When patents attack Android."The top legal officer lashed out the coalition that Apple and Microsoft formed to buy Novell patents and Nortel patents.Last month, Google was outbid by the 4.5 billion bid made by the winning consortium of companies that includes Apple, Microsoft, Research in Motion, Sony, Ericsson and EMC on Canadian company Nortel Network's patent portfolio.The Nortel portfolio, which is in all of the companies'best legal interests, includes patents on 3G and 4G wireless networking, optics, voice processing, semiconductors and more.Last December, an unnamed consortium of companies, organized by Microsoft and including Apple, EMC and Oracle, also outbid Google for nearly 900 patents of software company Novell.Patent litigation between technology companies have been flaring up particularly over mobile devices and technology.Last August, Oracle accused Google of infringing on patents related to Java, which the database giant acquired when it took ownership of Sun Microsystems in early 2010.Microsoft is suing device makers who use Android, including Barnes & Noble, Motorola and HTC.Drummond wrote that "We're also looking at other ways to reduce the anti-competitive threats against Android by strengthening our own patent portfolio. Unless we act, consumers could face rising costs for Android devices -- and fewer choices for their next phone."

WASHINGTON, Sept. 12 (Xinhua) -- An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, U.S. researchers find.Over the course of four weeks, mice genetically engineered to lack the gene for protein kinase C (PKC) epsilon consumed less of a nicotine-containing water solution than normal mice, and were less likely to return to a chamber in which they had been given nicotine. In contrast, normal mice steadily increased their consumption of nicotine solution while the mice lacking PKC epsilon did not.The study conducted by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco, appeared Monday in the online edition of the Proceedings of the National Academy of Sciences.In normal mice, as in humans, nicotine binds to a certain class of nicotinic receptors located on dopamine neurons, which causes dopamine to be released in the brain. Dopamine creates a feeling of enjoyment, and thus prompts a sense of reward. Researchers found that mice lacking PKC epsilon are deficient in these nicotinic receptors.The finding complements earlier research in which researchers found that mice genetically engineered to lack the PKC epsilon enzyme drank less alcohol than normal mice and were disinclined to return to a chamber in which they had been given alcohol."This could mean that these mice might not get the same sense of reward from nicotine or alcohol," said Gallo senior associate director and investigator Robert Messing. "The enzyme looks like it regulates the part of the reward system that involves these nicotinic receptors."The reward system is a complex of areas in the brain that affect craving for nicotine, alcohol and other addictive substances.The next step in the research, said Messing, would be to develop compounds that inhibit PKC epsilon. The ultimate goal, he added, would be medications that could be used "to take the edge off of addiction by helping people get over some of their reward craving."

KIEV, Aug. 2 (Xinhua) -- Ukraine's regional health authority declared Tuesday a cholera epidemic in the eastern region of Donetsk had ended.All 26 people who had been treated for the disease had been discharged from hospital, the press-service of the Donetsk Regional Sanitary and Epidemiological Service said on its official website.As of this week, no new cases had been registered, the statement said.The cholera outbreak hit eastern Ukraine in late May. The disease can cause rapid dehydration and death.The outbreak was believed to be associated with fish and drinking water supplies from the Sea of Azov.

SYDNEY, Aug. 2 (Xinhua) -- Australia's general practitioners ( GPs) will not back the idea of routine prostate cancer tests for men as young as 40 despite growing calls for regular screening, the nation's largest professional general practice organization said on Tuesday.Spokesman for the Royal Australian College of General Practitioners (RACGP), Professor Chris Del Mar said there was not enough solid evidence to suggest major benefits from routine screening and that current tests were unable to detect "nasty" and potentially deadly forms of prostate cancer from ones that will not cause any harm."The problem is you end up treating lots of people who don't need to be treated," Del Mar said, adding that treatment could leave men impotent and with incontinence problems."You will treat 20 times as many people than would have ever been bothered by it. We don't yet know that treating prostate cancer is better than not treating it. We are not sure it does any good and could be doing more harm," he said.On the other hand, Australia's urologists and pathologists both want men aged 40 and over who are worried about developing the disease to be offered tests.The Royal College of Pathologists (RCPA) on Tuesday released an official recommendation on routine screening for men aged 40 and over if they were concerned about prostate cancer.The pathologists argue that blood tests for prostate cancer in men under 50 can predict their future risk of developing the disease by measuring their prostate specific antigen levels (PSA).They say that men with high PSA levels for their age should be tested annually, while those PSA levels are below the average could be tested less frequently.Their call for more routine testing contrasts with recommendations for GPs, whose `Red Book' medical guide does not support regular screening.Instead, it suggests GPs should inform men aged 50-70 of the risks and benefits of screening and only test if the patient requests one.RACGP spokesman Del Mar, who co-wrote the RACGP's recommendations, said while the Red Book was being revised "we are not going to liberalize it".Prostate cancer is one of the most common forms of cancer in Australia.About 20,000 cases of prostate cancer are diagnosed each year, with 3,300 men dying.Given the debate around prostate cancer tests, the Royal College of Pathologists wants to work with GPs, urologists and other medical organizations to develop a consensus on how and when to test for the disease, in a similar way to how experts approach breast cancer."It would be a good outcome for prostate cancer if we worked towards developing more of an umbrella document which reflected consensus among different stakeholder organizations. ," RCPA President Paul McKenzie said.

来源：资阳报